BRD2 and Parkinson disease: In addition, another investigation has promulgated that NAT and another selective, potent, and neoteric antagonist of NK1 receptor, namely lanepitant (LY303870), markedly de-escalated the levodopa-precipitated anomalous, not controllable, and involuntary movements of muscles (dyskinesia), without influencing the promising medicinal outcomes of levodopa in animal rat models experiencing PD [126,127].